https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2025-01-23 / J Hematol Oncol 2025 Jan;18(1):9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2025-01-23 / J Hematol Oncol 2025 Jan;18(1):92025-01-23 00:00:002025-01-23 00:00:00WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-06-04 / Cancers (Basel) 2021 Jun;13(11)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-06-04 / Cancers (Basel) 2021 Jun;13(11)2021-06-04 00:00:002021-06-04 00:00:00Immunotherapeutic Approaches in Malignant Pleural Mesothelioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-05-19 / Vaccines (Basel) 2021 May;9(5)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-05-19 / Vaccines (Basel) 2021 May;9(5)2021-05-19 00:00:002021-05-19 00:00:00Long-Term Follow-Up of Mesothelioma Patients Treated with Dendritic Cell Therapy in Three Phase I/II Trials
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-07-01 / J Thorac Oncol 2020 Jul;15(7):e111-e113
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-07-01 / J Thorac Oncol 2020 Jul;15(7):e111-e1132020-07-01 00:00:002020-07-01 00:00:00Oncolytic Viral Therapy for Malignant Pleural Mesothelioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-03-12 / Front Oncol 2020;10:343
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-03-12 / Front Oncol 2020;10:3432020-03-12 00:00:002020-03-12 00:00:00Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-03-01 / J Immunother Cancer 2020 Mar;8(1)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-03-01 / J Immunother Cancer 2020 Mar;8(1)2020-03-01 00:00:002020-03-01 00:00:00T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesothelioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-02-27 / Cancers (Basel) 2020 Feb;12(3)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-02-27 / Cancers (Basel) 2020 Feb;12(3)2020-02-27 00:00:002020-02-27 00:00:00Photodynamic Therapy-Based Dendritic Cell Vaccination Suited to Treat Peritoneal Mesothelioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-02-21 / Front Oncol 2020;10:187
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-02-21 / Front Oncol 2020;10:1872020-02-21 00:00:002020-02-21 00:00:00Immunotherapy in Malignant Pleural Mesothelioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-02-01 / Transl Lung Cancer Res 2020 Feb;9(Suppl 1):S100-S119
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-02-01 / Transl Lung Cancer Res 2020 Feb;9(Suppl 1):S100-S1192020-02-01 00:00:002020-12-09 09:48:40Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-05-14 / BMJ Open 2019 05;9(5):e026779
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-05-14 / BMJ Open 2019 05;9(5):e0267792019-05-14 00:00:002019-05-14 00:00:00Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial
